This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kelland, L. R. Articles by Harrap, K. R. Search for Related Content PubMed PubMed Citation Articles by Kelland, L. R. Articles by Harrap, K. R.

Establishment and Characterization of an in Vitro Model of Acquired Resistance to Cisplatin in a Human Testicular Nonseminomatous Germ Cell Line¹

Drug Development Section, The Institute of Cancer Research, Belmont, Sutton, Surrey SM2 5NG, United Kingdom

Clinically, human testicular nonseminomatous germ cell tumors exhibit remarkable sensitivity to platinum-based chemotherapy. To define better the mechanistic basis for this unusual sensitivity, the biochemical determinants of platinum-induced cytotoxicity have been investigated in a human testicular tumor cell line (GCT27) established from a previously untreated patient and in an in vitro derived 5.6-fold cisplatin-resistant stable variant (GCT27cisR). Compared to 12 ovarian and 5 cervical human tumor cell lines, the parent GCT27 line was among the most sensitive to the cytotoxic effects of both cisplatin (dosage producing 50% inhibition, 0.2 µM) and carboplatin (dosage producing 50% inhibition, 2.9 µM), thus reflecting clinical data. A 4-day exposure sulforhodamine B-staining assay was used to determine that GCT27cisR was cross-resistant to carboplatin and iproplatin and the classical bifunctional alkylating agents melphalan and chlorambucil. Partial cross-resistance was observed to tetraplatin, methotrexate, and mitomycin C. No cross-resistance was observed to Adriamycin, etoposide, vinblastine, bleomycin, 1-ß-D-arabinofuranosylcytosine, and 5-fluorouracil. Intracellular cisplatin accumulation across the dose range 2.5–100 µM (for 2 h) was 1.6 ± 0.39-fold (mean ± SD) greater for the parent line. There was no significant difference in glutathione levels between the two lines. The acquired resistance line was 1.9-fold more resistant than the parent line to the cytotoxic effects of cadmium chloride. There was no significant difference between the two lines, however, in the total amounts of platinum bound to DNA after cisplatin exposure (25, 50, or 100 µM for 2 h). The removal of total platinum adducts from DNA was significantly faster for GCT27cisR compared to the parent line (half-times of removal, 32 and 67 h, respectively). These data suggest that the abnormal sensitivity of the parent testicular tumor cell line to platinum-containing anticancer drugs may be due predominantly to an inherent defect in the ability of these cells to remove platinum from their DNA. This defect is apparently lost in the acquired resistance counterpart. Reduced intracellular accumulation and increased cytoplasmic concentrations of metallothionein may also contribute, in part, to the acquisition of cisplatin resistance in this model.

¹ This study was supported by grants to the Institute of Cancer Research from the Cancer Research Campaign (United Kingdom) and the Medical Research Council, the Johnson Matthey Technology Centre, and Bristol Myers Sqibb Oncology.

² J. J. R. died on 10/10/90. This study is dedicated to his memory.

Received 10/16/91. Accepted 1/20/92.

This article has been cited by other articles:

				B. G. Blair, C. A. Larson, R. Safaei, and S. B. Howell Copper Transporter 2 Regulates the Cellular Accumulation and Cytotoxicity of Cisplatin and Carboplatin Clin. Cancer Res., July 1, 2009; 15(13): 4312 - 4321. [Abstract] [Full Text] [PDF]

				J. Renshaw, R. M. Orr, M. I. Walton, R. te Poele, R. D. Williams, E. V. Wancewicz, B. P. Monia, P. Workman, and K. Pritchard-Jones Disruption of WT1 gene expression and exon 5 splicing following cytotoxic drug treatment: Antisense down-regulation of exon 5 alters target gene expression and inhibits cell survival Mol. Cancer Ther., November 1, 2004; 3(11): 1467 - 1484. [Abstract] [Full Text] [PDF]

				G. Samimi, N. M. Varki, S. Wilczynski, R. Safaei, D. S. Alberts, and S. B. Howell Increase in Expression of the Copper Transporter ATP7A during Platinum Drug-Based Treatment Is Associated with Poor Survival in Ovarian Cancer Patients Clin. Cancer Res., December 1, 2003; 9(16): 5853 - 5859. [Abstract] [Full Text] [PDF]

				K. Katano, A. Kondo, R. Safaei, A. Holzer, G. Samimi, M. Mishima, Y.-M. Kuo, M. Rochdi, and S. B. Howell Acquisition of Resistance to Cisplatin Is Accompanied by Changes in the Cellular Pharmacology of Copper Cancer Res., November 15, 2002; 62(22): 6559 - 6565. [Abstract] [Full Text] [PDF]

				P. Perego, C. Caserini, L. Gatti, N. Carenini, S. Romanelli, R. Supino, D. Colangelo, I. Viano, R. Leone, S. Spinelli, et al. A Novel Trinuclear Platinum Complex Overcomes Cisplatin Resistance in an Osteosarcoma Cell System Mol. Pharmacol., March 1, 1999; 55(3): 528 - 534. [Abstract] [Full Text]